TrianglePacritinib (NCT07447817)
Pacritinib trial for Myelofibrosis (NCT07447817). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with intermediate- or high-risk myelofibrosis, an enlarged spleen, anemia and low platelets. Previous JAK-inhibitor treatment is excluded.
The idea: begin oral pacritinib, blocking JAK growth signaling. Add weekly oral selinexor only if blood-count checks allow; it keeps growth-control proteins inside the cell nucleus. Some patients remain on pacritinib alone. Researchers measure spleen shrinkage at 24 weeks and assess safety.
This phase 2 study plans 26 patients. John Mascarenhas leads; Mount Sinai in New York is the one US location listing recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.